<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>Latest Biology Technology from Bio-Medicine.Org</title>
<link>http://www.bio-medicine.org/biology-technology-1/</link>
<description>Latest Biology Technology lists</description>
<language>en-us</language>
<copyright>Copyright 2007. Bio-Medicine All Rights Reserved.</copyright>
<item>
<title><![CDATA[Vermillion Reports First Quarter 2012 Results]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Vermillion-Reports-First-Quarter-2012-Results-22243-1/</link>
<pubDate>Tue, 15 May 2012 01:43:45 MST</pubDate>
<description><![CDATA[AUSTIN, Texas, May 15, 2012 /- Vermillion, Inc. (NASDAQ:   VRML ), a leading molecular diagnostics company, reported financial and operational results for the first quarter ended March 31,&#160;2012.    Q1 2012 Operational Highlights     In Q1, the volume of OVA1&#174;, the company's flagship diagnostic test designed to help differentiate benign from malignant ovarian masses, was ge... ]]></description>
</item>
<item>
<title><![CDATA[OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/OrbusNeichs-Combo-Dual-Therapy-Stent-u2122-Demonstrates-Favorable-Clinical-and-Safety-Outcomes-at-12-Month-Follow-Up-22242-1/</link>
<pubDate>Tue, 15 May 2012 11:23:26 MST</pubDate>
<description><![CDATA[PARIS, May 15, 2012 /-&#160;OrbusNeich today announced that 12-month follow-up data from the REMEDEE study showed favorable clinical and safety outcomes involving the use of the company's Combo Dual Therapy Stent when compared to the TAXUS &#174;  Liberte &#174;  paclitaxel-eluting stent. The data were presented by Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in... ]]></description>
</item>
<item>
<title><![CDATA[Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Neuroendocrine-Carcinoma-Therapeutics---Pipeline-Assessment-and-Market-Forecast-to-2019-22241-1/</link>
<pubDate>Tue, 15 May 2012 08:10:32 MST</pubDate>
<description><![CDATA[NEW YORK, May 15, 2012 /- Reportlinker.com announces that a new market research report is available in its catalogue:    Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019    http://www.reportlinker.com/p0606218/Neuroendocrine-Carcinoma-Therapeutics---Pipeline-Assessment-and-Market-Forecast-to-2019.html#utm_source=prnewswire&amp;utm_medium=pr&amp... ]]></description>
</item>
<item>
<title><![CDATA[Cardium Presents First Quarter 2012 Financial Results and Recent Developments]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Cardium-Presents-First-Quarter-2012-Financial-Results-and-Recent-Developments-22240-1/</link>
<pubDate>Tue, 15 May 2012 08:10:06 MST</pubDate>
<description><![CDATA[SAN DIEGO, May 15, 2012 /- Cardium Therapeutics (NYSE Amex:   CXM ) today presented its financial results for the first quarter ended March 31, 2012, and other recent developments.   (Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO )    In addition to the announcement of first quarter 2012 financial results, Cardium reported its goals for 2012, which were outlined in t... ]]></description>
</item>
<item>
<title><![CDATA[Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Generex-Enhances-Antigen-Express-Scientific-Advisory-Board-for-the-AE37-Breast-Cancer-Vaccine-with-Renowned-Breast-Cancer-Researchers-22239-1/</link>
<pubDate>Tue, 15 May 2012 08:09:29 MST</pubDate>
<description><![CDATA[WORCESTER, Mass. and TORONTO, May 15, 2012 /- Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation of   the transition into pivotal Phase III trials, is pleased to announce today that the expertise of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical... ]]></description>
</item>
<item>
<title><![CDATA[Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Butamax-Granted-Core-Patent-for-Making-Biobutanol-and-Distillers-Grains-3B-Offers-Producers-Efficient--Low-Cost-Production-of-Biobutanol-22238-1/</link>
<pubDate>Tue, 15 May 2012 05:24:00 MST</pubDate>
<description><![CDATA[WILMINGTON, Del., May 15, 2012 /- Butamax&#8482; Advanced Biofuels, LLC announced today that the United States Patent and Trademark Office (USPTO) has granted Butamax Patent Number 8,178,328. The '328 patent covers a highly efficient engineered pathway for producing isobutanol from recombinant microorganisms at commercial scale.&#160; These novel microorganisms have been designed us... ]]></description>
</item>
<item>
<title><![CDATA[BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/BGI-Installs-Roche-GS-FLX+-System-to-Enhance-Long-Read-Sequencing-Capabilities-for-Genome-and-Transcriptome-Research-22237-1/</link>
<pubDate>Tue, 15 May 2012 05:23:44 MST</pubDate>
<description><![CDATA[BRANFORD, Connecticut and SHENZHEN, China, May 15, 2012 /-   BGI, one of the world's largest genomics organizations, announced today that a new Roche GS FLX+ System has been successfully installed at its facility in Shenzhen, China. The goal is to complement the existing array of short read sequencing technologies and enhance BGI's long read sequencing capability.   The GS FLX+ Syst... ]]></description>
</item>
<item>
<title><![CDATA[Are people with HIV/AIDS more prone to sudden cardiac death?]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Are-people-with-HIV-AIDS-more-prone-to-sudden-cardiac-death-3F-22236-1/</link>
<pubDate>Mon, 14 May 2012 07:39:56 MST</pubDate>
<description><![CDATA[	 What is the connection, if any, between sudden cardiac death and people with HIV/AIDS? And can that knowledge help prolong their lives?   	 In a comprehensive, 10-year UCSF study, researchers found patients with HIV/AIDS suffered sudden cardiac death at a rate four times higher than the general population.   	 "As part of my ongoing research in 2010, we were looking at every instance of sudden... ]]></description>
</item>
<item>
<title><![CDATA[Bio-hybrid device acts as 'thermostat' to control systemic inflammation in sepsis]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Bio-hybrid-device-acts-as-thermostat-to-control-systemic-inflammation-in-sepsis-22235-1/</link>
<pubDate>Mon, 14 May 2012 07:39:29 MST</pubDate>
<description><![CDATA[	 PITTSBURGH, May 14 - A small, external bioreactor holding human cells pumped out an anti-inflammatory protein to prevent organ damage and other complications in a rat with acute inflammation caused by bacterial products in a model of sepsis, according to a report from researchers at the University of Pittsburgh School of Medicine and the McGowan Institute for Regenerative Medicine. The findi... ]]></description>
</item>
<item>
<title><![CDATA[Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Oracle-chairman-Jeff-Henley-makes--2450-million-gift-to-UC-Santa-Barbara-22234-1/</link>
<pubDate>Mon, 14 May 2012 07:38:51 MST</pubDate>
<description><![CDATA[	 (Santa Barbara, Calif.)  Imagine an LED light with 20 times the efficiency of an incandescent bulb. Or a computer that can generate, transmit, and store data 100 times faster than those we use today. How much healthier would our planet be if we could turn waste heat into electricity, or improve the performance of low-cost solar cells, making them more efficient, and more accessible?    	 The (... ]]></description>
</item>
<item>
<title><![CDATA[You can't play nano-billiards on a bumpy table]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/You-cant-play-nano-billiards-on-a-bumpy-table-22233-1/</link>
<pubDate>Mon, 14 May 2012 07:38:38 MST</pubDate>
<description><![CDATA[	 There's nothing worse than a shonky pool table with an unseen groove or bump that sends your shot off course: a new study has found that the same goes at the nano-scale, where the "billiard balls" are tiny electrons moving across a "table" made of the semiconductor gallium arsenide.   	 These tiny billiard tables are of interest towards the development of future computing technologies. In a re... ]]></description>
</item>
<item>
<title><![CDATA[New research could mean faster computers and better mobile phones]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/New-research-could-mean-faster-computers-and-better-mobile-phones-22232-1/</link>
<pubDate>Mon, 14 May 2012 07:38:30 MST</pubDate>
<description><![CDATA[	     Graphene and carbon nanotubes could improve the electronics used in computers and mobile phones, reveals new research from the University of Gothenburg, Sweden.   	 Carbon nanotubes and graphene are both made up of carbon and have unique properties. Graphene comprises an atom-thick layer of carbon atoms, while carbon nanotubes can be likened to a graphene sheet that has been rolled up to f... ]]></description>
</item>
<item>
<title><![CDATA[New Daily Disposable Multifocal Contact Lenses from CooperVision Offer Comfort, Performance, Health, and Convenience to Fit Your Life]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/New-Daily-Disposable-Multifocal-Contact-Lenses-from-CooperVision-Offer-Comfort--Performance--Health--and-Convenience-to-Fit-Your-Life-22231-1/</link>
<pubDate>Mon, 14 May 2012 04:43:20 MST</pubDate>
<description><![CDATA[ROCHESTER, N.Y., May 14, 2012 /-&#160;More than one billion people worldwide have a vision condition called presbyopia(1), which is a natural decrease in the ability of the lens in the eye to change its shape to focus on close objects. We've all seen others struggle with trying to read menus and newspapers. Maybe it has even happened to you.   To combat this change in vision, which... ]]></description>
</item>
<item>
<title><![CDATA[Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Regenerative-Sciences-Receives--242M-Investment-for-Orthopedic-Stem-Cell-Initiatives-22230-1/</link>
<pubDate>Mon, 14 May 2012 10:50:39 MST</pubDate>
<description><![CDATA[DENVER, May 14, 2012 /- Regenerative Sciences, Inc., a company dedicated to advancing orthopedic care through non-surgical adult stem cell procedures, today announced that it has secured a $2M investment from philanthropist, visionary and businessman John C. Malone, PhD, chairman of Liberty Media Corporation. In addition to advancing Regenerative Sciences' clinical and lab-based ste... ]]></description>
</item>
<item>
<title><![CDATA[Novocure Announces Launch of Recurrent Glioblastoma Product Website]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Novocure-Announces-Launch-of-Recurrent-Glioblastoma-Product-Website-22229-1/</link>
<pubDate>Mon, 14 May 2012 10:50:25 MST</pubDate>
<description><![CDATA[PORTSMOUTH, N.H., May 14, 2012 /- In its ongoing effort to help patients, their caregivers and health care professionals easily find detailed information about its NovoTTF&trade; therapy for recurrent glioblastoma, Novocure&trade; today unveiled its U.S.-focused NovoTTF&trade; Therapy Website, found at  www.novottftherapy.com .   Novocure&trade;, a commercial stage private oncology... ]]></description>
</item>
<item>
<title><![CDATA[Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Shire-Facebook-Page-Increases-Awareness-of-Hereditary-Angioedema--28HAE-29-in-Support-of-First-HAE-Awareness-Day-May-16th-22228-1/</link>
<pubDate>Mon, 14 May 2012 10:50:09 MST</pubDate>
<description><![CDATA[LEXINGTON, Mass., May 14, 2012 /- Shire plc (LSE: SHP, NASDAQ:   SHPGY ), the global specialty biopharmaceutical company, today announced its support of the first global hereditary angioedema (HAE) awareness day, being held on May 16th, with a new Facebook page "Shire Supports HAE Awareness Day." Developed to help raise awareness of HAE, for every person who likes the Facebook page... ]]></description>
</item>
<item>
<title><![CDATA[Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Palatin-Technologies--Inc--Reports-Third-Quarter-Fiscal-Year-2012-Results-3B-Teleconference-and-Webcast-to-be-held-on-May-14--2012-22227-1/</link>
<pubDate>Mon, 14 May 2012 05:58:26 MST</pubDate>
<description><![CDATA[CRANBURY, N.J., May 14, 2012 /-&#160;Palatin Technologies, Inc. (NYSE Amex:   PTN ) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2012.&#160; Palatin reported a net loss of $6.0 million, or... ]]></description>
</item>
<item>
<title><![CDATA[US HIFU Adds Mark Carol, MD, As Chief Development Officer]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/US-HIFU-Adds-Mark-Carol--MD--As-Chief-Development-Officer-22226-1/</link>
<pubDate>Mon, 14 May 2012 05:56:37 MST</pubDate>
<description><![CDATA[CHARLOTTE, N.C., May 14, 2012 &#160;/-&#160;USHIFU, LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today that Mark Carol, MD, has joined the new management team as chief development officer. With more than 25 years of clinical practice and medical device industry experience, Dr. Carol will focus on continued devel... ]]></description>
</item>
<item>
<title><![CDATA[Functional Circulation LLC Receives Grand Challenges Explorations Grant for Groundbreaking Research in Global Health and Development]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Functional-Circulation-LLC-Receives-Grand-Challenges-Explorations-Grant-for-Groundbreaking-Research-in-Global-Health-and-Development-22225-1/</link>
<pubDate>Mon, 14 May 2012 05:54:45 MST</pubDate>
<description><![CDATA[NORTHBROOK, Ill., May 14, 2012  /PRNewswire-iReach/  --   Functional &#160; Circulation LLC   announced today that it is a  Grand Challenges Explorations  winner, an initiative funded by the  Bill &amp; Melinda Gates Foundation . Functional Circulation CEO John Brassil and colleagues will pursue an innovative global health and development research project titled "Smart Bowl Conveys Cassava to Ma... ]]></description>
</item>
<item>
<title><![CDATA[Syngenta and Devgen enter insect control research partnership]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Syngenta-and-Devgen-enter-insect-control-research-partnership-22224-1/</link>
<pubDate>Sun, 13 May 2012 10:24:49 MST</pubDate>
<description><![CDATA[BASEL, Switzerland, May 14, 2012       License to access novel insect control technology      New range of biological solutions for hard-to-control insects      Development of new commercial offers for growers      Syngenta and Devgen today announced a six-year global license and research agreement. The partnership will enable Syngenta to add RNA interference (RNAi) technology to its crop protec... ]]></description>
</item>
</channel>
</rss>
